ACADIA Pharmaceuticals Inc (ACAD.OQ) Quote| Reuters.com
Edition:
United States

ACADIA Pharmaceuticals Inc (ACAD.OQ)

ACAD.OQ on NASDAQ Stock Exchange Global Select Market

31.66USD
28 Jun 2016
Change (% chg)

-- (--)
Prev Close
$31.66
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
861,225
52-wk High
$51.98
52-wk Low
$16.65

ACAD.OQ

Chart for ACAD.OQ

About

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system disorders. The Company's lead drug candidate, NUPLAZID (pimavanserin), is under development for the treatment of Parkinson's disease psychosis (PDP). NUPLAZID is a... (more)

Overall

Beta: 3.44
Market Cap(Mil.): $3,428.84
Shares Outstanding(Mil.): 113.16
Dividend: --
Yield (%): --

Financials

  ACAD.OQ Industry Sector
P/E (TTM): -- 38.36 34.67
EPS (TTM): -1.68 -- --
ROI: -47.57 -6.77 14.11
ROE: -47.60 -6.10 15.33

BRIEF-Acadia's Nuplazid available for treatment of hallucinations, delusions associated with Parkinson's

* Nuplazid (pimavanserin) now available for treatment of hallucinations and delusions associated with Parkinson's disease psychosis Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

May 31 2016

BRIEF-Acadia Pharmaceuticals reports Q1 loss per share $0.45

* Acadia pharmaceuticals reports first quarter 2016 financial results

May 05 2016

U.S. approves first drug for psychosis linked to Parkinson's

Acadia Pharmaceuticals Inc's drug for psychosis linked to Parkinson's disease was approved in the United States on Friday, becoming the first treatment for the condition to get a nod in the country.

Apr 29 2016

Acadia drug approval could clear way for Axovant dementia therapy

An imminent ruling on Acadia Pharmaceuticals Inc's drug for Parkinson's disease psychosis is being closely watched by a Bermuda-based company with a similar treatment for dementia.

Apr 28 2016

Acadia drug approval could clear way for Axovant dementia therapy

April 28 An imminent ruling on Acadia Pharmaceuticals Inc's drug for Parkinson's disease psychosis is being closely watched by a Bermuda-based company with a similar treatment for dementia.

Apr 28 2016

FDA panel backs Acadia drug for psychosis linked to Parkinson's

An advisory panel to the U.S. Food and Drug Administration backed an approval for Acadia Pharmaceuticals Inc's drug for psychosis related to Parkinson's disease.

Mar 29 2016

UPDATE 2-FDA panel backs Acadia drug for psychosis linked to Parkinson's

March 29 An advisory panel to the U.S. Food and Drug Administration backed an approval for Acadia Pharmaceuticals Inc's drug for psychosis related to Parkinson's disease.

Mar 29 2016

BRIEF-Acadia Pharma says FDA panel votes 12 to 2 on benefit-risk profile of its drug for Parkinson's Disease psychosis

* Fda advisory committee votes 12 to 2 that benefits of acadia pharmaceuticals' nuplazid(tm) (pimavanserin) for the treatment of psychosis associated with parkinson's disease outweigh the risks Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Mar 29 2016

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $34.44 +0.64
Johnson & Johnson (JNJ.N) $118.23 +1.68
AstraZeneca plc (AZN.L) 4,286.50p +13.00
Eli Lilly and Co (LLY.N) $75.15 +0.26
Bristol-Myers Squibb Co (BMY.N) $72.01 +1.69
Bristol-Myers Squibb Co (BMYMP.PK) $1,231.90 --
Allergan, Inc. (AGN.N) $227.72 +10.24

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : New Constructs, LLC
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ Quantitative Report
$115.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.